Studies of catecholamine metabolism in schizophrenia/psychosis-I

Neuropsychopharmacology

Volumn 8, Issue 2, 1993, Pages 97-109

  Maas, James W ^a   Contreras, Salvador A ^b   Miller, Alexander L ^a   Bennan, Nancy ^d   Bowden, Charles L ^a   Javors, Martin A ^a   Seleshi, Emiias ^c   Weintraub, Susan ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Dopamine; Hva; Mhpg; Neuroleptic actions; Norepinephrine; Psychosis; Renal clearance; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; DEBRISOQUINE; DOPAMINE; HOMOVANILLIC ACID; NORADRENALIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD PLATELETS; CATECHOLAMINES; DEBRISOQUIN; DOUBLE-BLIND METHOD; HOMOVANILLIC ACID; HUMAN; IN VITRO; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGE; MONOAMINE OXIDASE; PSYCHOMETRICS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027538431     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.1993.11     Document Type: Article

References (86)

1. Anggard E, Lewander T, Sjoquist B (1974): Determination of homovanillic acid turnover in man. Life Sci 15:111-121
2. Antelman SM, Caggiula AR (1977): Norepinephrine-dopamine interactions and behavior: A new hypothesis of stress-related interactions between brain norepinephrine and dopamine is proposed. Science 195:646-653
3. Ashcroft GW, Crawford TBB, Eccleston D, Sharman DF, Mac-Dougall EJ, Stanton JB, Binns JK (1966): 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet 2:1049-1052
4. Bacopoulos ND, Heninger GR, Roth RH (1978): Effects of haloperidol and probenecid on plasma and CSF dopamine metabolites in the rhesus monkey (Macaca Mulatta). Life Sci 23:1805-1812
5. Bacopoulos NG, Hattox SE, Roth RH (1979): 3,4-Dihy-droxyphenylacetic acid and homovanillic acid in rat plasma: Possible indicators of central dopaminergic activity. Eur J Pharmacol 56:225-236
6. Berger PA, Faull KF, Kilkowski J, Anderson PJ, Kraemer H, Davis KL, Barchas JD (1980): CSF monoamine metabolites in depression and schizophrenia. Am J Psychiatry 137:174-180
7. Bowers MB Jr (1973): 5-Hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines. Psy-chopharmacologia 28:309-318
8. Bowers MB Jr (1978): CSF acid monoamine metabolites in psychotic syndromes: What might they signify? Biol Psychiatry 13:375-383
9. Bowers MB Jr (1980): Biochemical processes in schizophrenia: An update. In Keith SJ, Mosher LR (eds), Special Report, Schizophrenia, 1980. Bethesda, National Institute of Mental Health, pp 27-37
10. Bowers MB Jr, Heninger GR, Gerbode FA (1969): Cerebrospinal fluid, 5-hydroxyindoleacetic acid and homovanilc acid in psychiatric patients. Neuropharmacology 8:255-262
11. Bowers MB Jr, Swigar Jatlow PI, Goicoechea N (1984): Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 45:248-251
12. Breier A, Wolkowitz OM, Roy A, Potter WZ, Pickar D (1990): Plasma norepinephrine in chronic schizophrenia. Am Psychiatry 147:1467-1470
13. Buhler U, Da Prada M, Haefely W, Picotti GB (1978): Plasma adrenaline, noradrenaline and dopamine in man and different animal species. J Physiol 276:311-320
14. Bunney BS, Grace AA (1978): Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sci 23:1715-1728
15. Bunney WE Jr (1978): Drug therapy and psychobiological research advances in the psychoses in the past decade. Am J Psychiatry 135:8-13
16. Carlsson A, Lindqvist M (1963): Effect of chlorpromazine or haloperidol on formation of 3-methoxytyr^arnine and nor-metanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144
17. Davidson M, Kahn RS, Knott P, Kaminsky R, Cooper M, DuMont K, Apter S, Davis KL (1991a): Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry 48:910-913
18. Davidson M, Kahn RS, Powchik P, Warne P, Losonczy MF, Kaminsky R, Apter S, Jaff S, Davis KL (1991b): Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 48:73-76
19. Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ (1988): Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45:564-567
20. Davis KL, Davidson M, Mohs RC, Kendler KS, Davis BM, Johns CA, DeNigris Y, Horvath TB (1985): Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science 227:1601-1602
21. Davis KL, Kahn RS, Ko G, Davidson M (1991): Dopamine n schizophrenia: A review and reconceptualization. Am j Psychiatry 148:1474-1486
22. Hchisak MA, Polinsky RJ, Elbert MH, Modlin LT, Kopin IJ (1979): Kinetics of homovanillic acid and determination of its production rate in the rhesus monkey. Life Sci 24:1493-1502
23. Hsworth JD, Redmond DE, Roth RH (1982): Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates. Brain Res 235:115-124
24. Farde L, Wiesel F-A, Halldin C, Sedvall G (1988): Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
25. Farley IJ, Price KS, McCullough E, Deck JHN, Hordynsky W, Hornykiewicz O (1978): Norepinephrine in chronic paranoid schizophrenia: Above-normal levels in limbic forebrain. Science 200:456-457
26. Farley IJ, Shannak KS, Hornykiewicz O (1980): Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased dopamine receptor sensitivity. Adv Biochem PsychopharmacoI 21:427-433
27. Freedman R, Kirch D, Bell J, Adler LE, Pecevich M, Pacht-man E, Denver P (1982): Clonidine treatment of schizophrenia: double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatr Scand 65:35-45
28. Gershon S, Hekimian LJ, Floyd A Jr, Hollister LE (1967): a-Methyl-p-tyrosine (AMT) in schizophrenia. Psycho-pharmacologia 11:189-194
29. Glazer WM, Charney DS, Heninger GR (1987): Noradrenergic function in schizophrenia. Arch Gen Psychiatry 44:898-904
30. Gomes UCR, Shanley BC, Potgieter L, Roux JT (1980): Noradrenergic overactivity in chronic schizophrenia: Evidence based on cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations. Br J Psychiatry 137:346-351
31. Grenhoff J, Svensson TH (1989): Clonidine modulates dopamine cell bring in rat ventral tegmental area. Eur J Pharmacol 165:11-18
32. Guldberg HC, Yates CM (1968): Some studies of the effects of chlorpromazine, reserpine and dihydroxphenylalanine on the concentration of homovanillic acid, 3,4-dihydroxy-phenylacetic acid and 5-hydroxyindol-3-ylacetic acid in ventricular cerebrospinal fluid of the dog using the technique of serial sampling of the cerebrospinal fluid. Br J Pharmacol Chemother 33:457-471
33. Haracz JL (1982): The dopamine hypothesis: An overview of studies with schizophrenic patients. Schizophrenia Bull 8:438-469
34. Harris PQ, Brown SJ, Friedman MJ, Bacopoulos NG (1984): Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics. Biol Psychiatry 19: 849-860
35. Helger R, Rindfrey H, Eilgenfeldt J (1974): Eine methode zur direkten bestimmung des creatinins in serum und ham ohne enteiwissung nach einer modifizierten Jaffe-Methode. Z Klin Chern Klin Biochem 12:344-349
36. Honigfeld G, Klett CJ (1965): The Nurses' Observation Scale for inpatient evaluation. J Clin Psychol 21:65-71
37. Hornykiewicz O (1978): Psychopharmacological implications of dopamine and dopamine antagonists: A critical evaluation of current evidence. Neuroscience 3:773-783
38. Javaid JI, Sharma RP, Janicak PG, Davis JM (1990): Plasma HVA in psychiatric patients: Longitudinal studies. Psy-chopharmacol Bull 26:361-365
39. Joseph MH, Baker HF, Johnstone EC, Crow TJ (1976): Determination of 3-methoxy-4-hydroxyphenylglycol conjugates in urine. Application to the study of central noradrenaline metabolism in unmedicated chronic schizophrenic patients. Psychopharmacology 51:47-51
40. Karoum F, Wyatt R, Costa E (1974): Estimation of the contribution of peripheral and central noradrenergic neurones to urinary 3-methoxy-4-hydroxyphenylglycol in the rat. Neuropharmacology 13:165-176
41. Kemali D, Del Vecchio M, Maj M (1982): Increased nonadrenaline levels in CSF and plasma of schizophrenic patients. Biol Psychiatry 17:711-717
42. Kendler KS, Mohs RC, Davis KL (1983): The effects of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatry Res 8:215-224
43. Kitchin AH, Turner RWD (1966): Studies on debris oquin sulfate. Br Med J 2:728-731
44. Ko GN, Jimerson DC, Wyatt RJ, Bigelow LB (1988): Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype. Arch Gen Psychiatry 45:842-846
45. Kopin IJ, Bankiewicz KS, Harvey-White J (1988): Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: Validation in monkeys treated with PTP. J Neuropsychopharm 1: 119-125
46. Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ (1983): Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 219:73-75
47. Lambert GW, Eisenhofer G, Cox HS, Horne M, Kalff V, Kelly M, Jennings GL, Esler MD (1991): Direct determination of homov^anilc acid release from the human brain, an indicator of central dopaminergic activity. Life Sci 49: 1061-1072
48. Maas JW, Hattox SE, Martin DM, Roth RH (1977): A direct method for studying brain amine metabolism in awake animals. In Usdin E, Weiner N, Youdim MBH (eds), Structure and Function of Monoamine Enzymes. New York, Marcel Dekker, pp 811-820
49. Maas JW, Hattox SE, Landis DH (1979a): Differential effects on brain catecholamines by debrisoquin. Biochem Phar-macoI 28:3153-3156
50. Maas JW, Hattox SE, Martin DM, Landis DH (1979b): A di-rectmethod for deteg dopamine synthesis and output of dopamine metabolites from brain in awake animals. J Neurochem 32:839-843
51. Maas JW, Hattox SE, Greene NM, Landis DH (1980): Estimates of dopamine and serotonin synthesis by the awake human brain. J Neurochem 34:1547-1549
52. Maas JW, Contreras SA, Bowden CL, Weintraub SE (1985): Effects of debrisoquin on CSF and plasma HVA concentrations in man. Life Sci 36:2163-2170
53. Maas JW, Contreras SA, Seleshi E, Bowden CL (1988): Dopamine metabolism and disposition in schizophrenic patients: studies using debrisoquin sulfate. Arch Gen Psychiatry 45:553-559
54. Medina MA, Giachetti A, Shore PA (1969): On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquin. Biochem Pharmacol 18:891-901
55. Meltzer HY, Stahl SM (1976): The dopamine hypothesis of schizophrenia: A review. Schizophrenia Bull 2:19-76
56. Miller AL, Keenan RW, Maas JW, Asch RH (1987): Disposition of homovanillic acid in the primate. Metab Brain Dis 2:207-212
57. Murphy DL, Wright C, Buchsbaum M, Nichols A, Costa JL, Wyatt RJ (1976): Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med 16:254-265
58. Muscettola G, Barbato G, de Bartolomeis A, Monteleone P, Pickar D (1990): Plasma IHVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. Psychiatry Res 33:259-267
59. Nasrallah HA, Donnelly EF, Bigelow LB, Rivera-Calimlim L, Rogol A, Potkin S, Rauscher FP, Wyatt RJ, Gillin JC (1977): Inhibition of dopamine synthesis in chronic schizophrenia: Clinical ineffectiveness of metyrosine. Arch Gen Psychiatry 34:649-655
60. Nyback H, Berggren B-M, Hindmarsh T, Sedvall G, Wiesel F-A (1983): Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Res 9:301-308
61. Overall J, Gorham DR (1992): The Brief PsychiatriC Rating Scale. Psycholog Rep 10:799-812
62. Persson T, Roos BE (1969): Acid metabolites from mono^arnines in cerebrospinal fluid of chronic schizophrenics. Br J Psychiatry 115:95-98
63. Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM (1984): Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225:954-957
64. Pickar D, Labarca R, Doran A, Wolkowitz OM, Roy A, Breier A, Lonnoila M, Paul SM (1986): Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 43:669-676
65. Pletscher A, Bartholini G, Tissot R (1967): Metabolic fate of [14C]DOPA in cerebrospinal fluid and blood plasma of humans. Brain Res 4:106-109
66. Potter WZ, Hsiao JK, Goldman SM (1989): Effects of renal clearance on plasma concentrations of homovanillic arid. Arch Gen Psychiatry 46:558-562
67. Riddle A, Leckman JF, Cohen DJ, Anderson M, Ort SI, Caruso A, Shaywitz BA (1986): Assessment of central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration. J Neural Transm 67:31-43
68. Rimon R, Roos B-E, Rakkolainen V, Alanen Y (1971): The content of 5-hydroxyindoleacetic acid and homovanillic arid in the cerebrospinal fluid of patients with acute schizophrenia. J Psychosom Res 15:375-378
69. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1:5-15
70. Snider SR, Kuchel O (1983): Dopamine: An important neurohormone of the sympathoadrenal system. Significance of increased peripheral dopamine release for the human stress response and hypertension. Endocrin Rev 4: 291-309
71. Spitzer RL, Endicott J (1979): Schedule for Affective Disorders and Schizophrenia. 3rd ed. New York, Biometrics Research Division, New York State Psychiatric Institute
72. Spitzer RL, Endicott J, Robins E (1978): Research Diagnostic Criteria: Rationale and reliability. Arch Gen Psychiatry 35:773-782
73. Stein L, Wise CD (1971): Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 171:1032-1036
74. Sternberg DE, van Kammen DP, Lake CR, Ballenger JC, Marder SR, Bunney WE Jr (1981): The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry 138:1045-1051
75. Sternberg DE, Charney DS, Heninger GR, Leckman JF, Halstad M, Landis Dh (1982): Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of cloni-dine in schizophrenic patients and normal controls. Arch Gen Psychiatry 39:285-289
76. Swann AC, Maas JW, Hattox SE, Landis DH (1980): Catecholamine metabolites in human plasma as indices of brain function: Effects of debrisoquin. Life Sci 27:1857-1862
77. Thiemann S, Csernansky JG, Berger PA (1987): Rating scales in research: The case of negative symptoms. Psychiatry Res 20:47-55
78. Tomlinson DR, Mayor D (1973): The effects of guanethidine, bretylium and debrisoquine on the accumulation of noradrenaline in constricted postganglionic sympathetic nerves in vitro. Eur J Pharmacol 21:161-170
79. van Kammen DP (1977): GABA and the dopamine hypothesis of schizophrenia. Am J Psychiatry 134:138-143
80. van Kammen DP, Antelman S (1984): Impaired noradrenergic transmission in schizophrenia? Life Sci 34: 1403-1413
81. van Kammen DP, Peters JL, van Kammen WB, Rosen J, Yao JK, McAdam D, Linnoila M (1989): Clonidine treatmentcf schizophrenia: Can we predict treatment response? Psychiatry, Res 27:297-311
82. Yajlkmen DP, Peters J, Yao J, van Kammen WB, Neylan T, Shaw D, Linnoila M (1990): Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psy-chatry 47:161-168
83. Van Loon GR, Schwartz L, Sole MJ (1979a): Plasma dopamine responses to standing and exercise in man. Life Sci 24:2273-2278
84. Van Loon GR, Sole MJ, Bain J, Ruse JL (1979b): Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28:425-434
85. van Praag HM (1977): The significance of dopamine for the mode of action of neuroleptics and pathogenesis of schizophrenia. Br J Psychiatry 130:463-474
86. Winblad B, Bucht G, Gottfries CG, Roos BE (1979): Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatr Scand 60:17-28